Mode
Text Size
Log in / Sign up
Phase 3 N=31 Treatment

Savella in Treatment for Provoked Vestibulodynia

Vestibulodynia · Vulvodynia

Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcome: Primary: Pain Rating Index — 12.3 units on a scale — p=.001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Milnacipran (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
University of Tennessee
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Rating Index
12.3 .001 sig
SECONDARY
Tampon Pain
2.45 .003 sig
SECONDARY
Coital Pain
3.43 .001 sig
SECONDARY
24-hour Vulvar Pain
0.73 <.001 sig

Summary

The primary aim of this study is to determine the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD), a centrally mediated pain syndrome similar to fibromyalgia, that is characterized by severe pain in the vestibule (outer vagina). The investigators will also determine whether associated symptoms in PVD, including psychological distress, impairment of sexual function, physical function, and quality of life, are correlated with a reduction in vulvar pain.

Eligibility Criteria

Inclusion Criteria

  • women between 18-54 years of age,
  • 'Friedrich's Criteria' must be met (report greater than six continuous months of vulvar symptoms including insertional dyspareunia or pain to touch, demonstrate on physical exam moderate to severe tenderness to light touch, localized to the vulvar vestibule [positive Cotton Swab Test] and demonstration of variable degrees of erythema of the vestibule),
  • an average pain level of "4" or greater on the 10-point tampon test and/or an average pain level of "4" or greater on the sexual intercourse pain scale(0 = no pain at all; 10 = worse pain ever) during the 2-week screening period(see Study Parameters Section), and
  • willing to use two forms of contraception during the study.

Exclusion Criteria

  • other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, and atrophic vaginitis (presence of a maturation index),
  • previous vestibulectomy,
  • active vaginal infection,
  • neuropathology, including seizure disorder or syncopal episodes,
  • pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study,
  • breastfeeding,
  • major medical illness including chronic liver disease/hepatic impairment, renal impairment, narrow-angle glaucoma, or uncontrolled hypertension,
  • major psychiatric illness including substance abuse,
  • multiple allergies (greater than three drugs or environmental agents),
  • use of centrally-acting agents, including monoamine oxidase inhibitors, benzodiazepines, opiates, muscle relaxants, and antidepressants within 2 weeks of randomization and during the study, and
  • use of topical lidocaine, within 2 weeks of randomization and during the study, as it has shown to be an effective treatment in some women, while worsening symptoms in others. Subjects will be permitted to take acetaminophen, aspirin, or a nonsteroidal anti-inflammatory drug as rescue medication. They will be provided with a list of allowable escape medications and those which would constitute a protocol deviation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01304589). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search